Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Stock Sees Buying Interest After The News

August 31, 2021

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) jumped 8%after announcing that the US FDA’s Pulmonary, Allergy, and Critical Care Division had approved its Investigational New Drug application for its flagship drug candidate, trans sodium crocetinate (TSC). Currently, the company has open TSC INDs with 4 FDA divisions, including Cardiology and Nephrology, Pulmonary, Allergy and Critical Care, Oncology and Neurology that the company believes will support the product candidate’s wide therapeutic potential. The company…

Read More >>

Diffussion Pharma Inc. (NASDAQ:DFFN) Stock Attempts To Rebound: How to Trade Now?

August 11, 2021

Diffussion Pharma Inc. (NASDAQ:DFFN) jumped 4.5% on no company-specific news or release. Recently, the company released a topline result for the phase 1 study of its flagship product, trans sodium crocetinate (TSC). The company used transcutaneous oxygen monitoring hg in the trial to assess direct TSC pharmacodynamics effects on peripheral oxygenation of tissue in healthy individuals. The topline findings were based on primary endpoint data analysis which showed a promising…

Read More >>